UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 65 filers reported holding UROGEN PHARMA LTD in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $417,000 | 0.0% | 47,900 | +9.1% | 0.00% | – |
Q4 2021 | $417,000 | -43.5% | 43,900 | 0.0% | 0.00% | – |
Q3 2021 | $738,000 | +10.1% | 43,900 | 0.0% | 0.00% | – |
Q2 2021 | $670,000 | -19.1% | 43,900 | +3.3% | 0.00% | -100.0% |
Q1 2021 | $828,000 | +8.1% | 42,500 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $766,000 | -6.6% | 42,500 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $820,000 | -21.2% | 42,500 | +6.8% | 0.00% | 0.0% |
Q2 2020 | $1,040,000 | +69.1% | 39,800 | +15.4% | 0.00% | 0.0% |
Q1 2020 | $615,000 | -45.8% | 34,500 | +1.5% | 0.00% | 0.0% |
Q4 2019 | $1,135,000 | +41.7% | 34,000 | +1.2% | 0.00% | 0.0% |
Q3 2019 | $801,000 | -30.8% | 33,600 | +4.3% | 0.00% | 0.0% |
Q2 2019 | $1,157,000 | -2.7% | 32,200 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $1,189,000 | +51.7% | 32,200 | +76.9% | 0.00% | 0.0% |
Q4 2018 | $784,000 | -3.4% | 18,200 | +5.8% | 0.00% | 0.0% |
Q3 2018 | $812,000 | -5.1% | 17,200 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $856,000 | – | 17,200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |